PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

Striking brain similarities have been detected in patients who experience Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), in ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

One of the most agonizing experiences a cancer patient suffers is waiting without knowing: waiting for a diagnosis, waiting ...

AI technology is everywhere, from phones to drive-through ordering systems. Given that companies like Google, Microsoft and ...

Interior Design Show returned in late January to the 180,000-square-foot North Building of the Metro Toronto Convention ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) fell 21% today, diverging from the company's recent ...

If Florida Republicans are looking for a smooth transition from DeSantis to whoever comes next, they've likely misjudged the ...

We do not need to believe in Platonic philosopher-kings to believe that it is good for our leaders to be equipped with the ...